Trio of VCs launch­es Gael­ic-in­spired Aer Ther­a­peu­tics with $36M to prove it­self in COPD around 2025

North Car­oli­na biotech Aer Ther­a­peu­tics emerged Thurs­day with $36 mil­lion in ven­ture cap­i­tal fund­ing to run a Phase I study in Aus­tralia this year and bankroll a mid-stage test next year in chron­ic ob­struc­tive pul­monary dis­ease.

The up­start is work­ing off an in­haled small mol­e­cule out of the lab of Uni­ver­si­ty of Cal­i­for­nia San Fran­cis­co re­searcher John Fahy, with the goal of tar­get­ing spe­cif­ic pa­tients who have mu­cus plugs or clots in their air­way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER